Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Arvada Therapeutics, Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner in 1 distinct art unit. This indicates a very concentrated prosecution effort at the present time. The focus within 1 distinct art unit suggests that the technology being pursued is specialized and falls under a specific set of examination guidelines within the biotechnology field.
The busiest examiner for this portfolio is REDDIG, PETER J, who is handling the 1 pending office action. Since there is only 1 distinct examiner involved, the company's current prosecution is centralized. Practitioners should focus on the specific feedback and examination style of this examiner to advance the pending application. This centralized prosecution structure allows for a very targeted strategy, but it also means that the company does not have other pending matters to balance out any difficulties encountered with this 1 distinct examiner. Effectively managing this 1 pending office action is critical for the company's current intellectual property objectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18333728 | DSG2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19 | REDDIG, PETER J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18333728 | DSG2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19 | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18333728 | DSG2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19 | REDDIG, PETER J | 1646 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial